Table S3  Heterogeneity factors analysis of tumor volume 
Heterogeneity factors	Breast cancer               	Hepatomacellular carcinoma	Prostate cancer	
	I2 (%)     p-value        n	I2 (%)    p-value          n	I2 (%)   p-value            n	
Cell lines derivation
human
animal 	 
0.0       0.480         2
92.2      0.000         11

human                   5	
human                    3	
Strain of animal
mice
rats
	
90.0      0.000         11
92.5      0.000         2
	mice                     5	mice                      3	
Immunology function of model animal
immunocompetent
immunocompromised 	
87.3      0.000         8
92.9      0.000         5	immunocompetent         5	immunocompetent          3	

Administration of drug
ip
po
Iv

93.7      0.000         6
81.7      0.000         6
NA       NA           1	ip                       5	ip                        3   	
Transplant tumor location
sc
orthortopic
NA	
NA       NA           1
90.2      0.000         12
NA       NA           0	
NA           NA         1
21.6         0.259        2
0.0          0.662        2	sc                        3	

Dosage range of FTY720
≤ 25 mg/kg/w
25 mg/kg/w~50 mg/kg/w 
≥ 50 mg/kg/w
NA	

88.2     0.000         9
92.5     0.000         2
NA      NA           1
NA      NA           1	

≥ 50/kg/w                5	
NA         NA           1
NA         NA           1
NA         NA           1
NA         NA           0	

Age
In breast cancer,
≤ 8 weeks,
> 8 weeks,
NA,
In hepatomacellular carcinoma,
NA
In prostate cancer,
< 6 weeks
> 6 weeks
NA	

91.3     0.000         8
91.3     0.000         3
42.8     0.186         2	

NA          NA         5	

NA         NA          1  
NA         NA          1
NA         NA          1	
Notice: Green indicated for the significant heterogeneity.